

References

S-5044

1. Rome BN, Kramer DB, Kesselheim AS. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. *JAMA*. Jan 2014; 311(4): 385-91. PMID 24449317
2. Food and Drug Administration. Boston Scientific Recalls EMBLEM S-ICD Subcutaneous Electrode (Model 3501) Due to Risk of Fractures. February 10, 2021. <https://www.fda.gov/medical-devices/medical-device-recalls/boston-scientific-recalls-emblem-s-icd-subcutaneous-electrode-model-3501-due-risk-fractures>. Accessed April 3, 2022.
3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med*. Dec 26 1996; 335(26): 1933-40. PMID 8960472
4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. Mar 21 2002; 346(12): 877-83. PMID 11907286
5. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. *N Engl J Med*. Nov 27 1997; 337(22): 1569-75. PMID 9371853
6. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med*. Dec 16 1999; 341(25): 1882-90. PMID 10601507
7. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med*. Jan 20 2005; 352(3): 225-37. PMID 15659722
8. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med*. Dec 09 2004; 351(24): 2481-8. PMID 15590950
9. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. *N Engl J Med*. Oct 08 2009; 361(15): 1427-36. PMID 19812399
10. Raviele A, Bongiorno MG, Brignole M, et al. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BETA-blocker STRategy plus ICD trial. *Europace*. Jul 2005; 7(4): 327-37. PMID 16028343

11. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med*. May 20 2004; 350(21): 2151-8. PMID 15152060
12. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med*. May 20 2004; 350(21): 2140-50. PMID 15152059
13. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. *J Am Coll Cardiol*. May 21 2003; 41(10): 1707-12. PMID 12767651
14. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). *Circulation*. Mar 26 2002; 105(12): 1453-8. PMID 11914254
15. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. *N Engl J Med*. Sep 29 2016; 375(13): 1221-30. PMID 27571011
16. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. *Heart*. Nov 2015; 101(22): 1800-6. PMID 26269413
17. Wolff G, Lin Y, Karathanos A, et al. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. *Clin Res Cardiol*. Jul 2017; 106(7): 501-513. PMID 28213711
18. Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. *J Cardiovasc Electrophysiol*. Jun 2017; 28(6): 659-665. PMID 28316104
19. Akel T, Lafferty J. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis. *Cardiovasc Ther*. Jun 2017; 35(3). PMID 28129469
20. Golwala H, Bajaj NS, Arora G, et al. Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis. *Circulation*. Jan 10 2017; 135(2): 201-203. PMID 27993908
21. Wasiak M, Tajstra M, Kosior D, et al. An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis. *Cardiol J*. Apr 12 2021. PMID 33843044
22. Earley A, Persson R, Garlitski AC, et al. Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review. *Ann Intern Med*. Jan 21 2014; 160(2): 111-21. PMID 24592496

23. Fontenla A, Martinez-Ferrer JB, Alzueta J, et al. Incidence of arrhythmias in a large cohort of patients with current implantable cardioverter-defibrillators in Spain: results from the UMBRELLA Registry. *Europace*. Nov 2016; 18(11): 1726-1734. PMID 26705555
24. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. *Circ Heart Fail*. Sep 01 2012; 5(5): 552-9. PMID 22821634
25. Magnusson P, Gadler F, Liv P, et al. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery. *J Cardiovasc Electrophysiol*. Oct 2015; 26(10): 1088-94. PMID 26178879
26. Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. *Heart Rhythm*. Nov 2010; 7(11): 1616-22. PMID 20816872
27. Hernandez-Ojeda J, Arbelo E, Borrás R, et al. Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators: Long-Term Follow-Up. *J Am Coll Cardiol*. Oct 17 2017; 70(16): 1991-2002. PMID 29025556
28. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. *J Am Coll Cardiol*. Mar 10 2015; 65(9): 879-88. PMID 25744005
29. Dores H, Reis Santos K, Adragao P, et al. Long-term prognosis of patients with Brugada syndrome and an implanted cardioverter-defibrillator. *Rev Port Cardiol*. Jun 2015; 34(6): 395-402. PMID 26028488
30. Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*. Jan 2014; 11(1): 58-66. PMID 24120999
31. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm*. Jul 2014; 11(7): 1305-23. PMID 24819193
32. Plitt A, Dorbala S, Albert MA, et al. Cardiac sarcoidosis: case report, workup, and review of the literature. *Cardiol Ther*. Dec 2013; 2(2): 181-97. PMID 25135396
33. Mantini N, Williams B, Stewart J, et al. Cardiac sarcoid: a clinician's review on how to approach the patient with cardiac sarcoid. *Clin Cardiol*. 2012; 35(7): 410-5. PMID 22499155
34. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. *J Am Coll Cardiol*. Apr 29 2008; 51(17): 1685-91. PMID 18436121

35. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. *Circulation*. Mar 1993; 87(3): 800-7. PMID 8443901
36. Alexander ME, Cecchin F, Walsh EP, et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. *J Cardiovasc Electrophysiol*. Jan 2004; 15(1): 72-6. PMID 15028076
37. Lewandowski M, Sterlinski M, Maciag A, et al. Long-term follow-up of children and young adults treated with implantable cardioverter-defibrillator: the authors' own experience with optimal implantable cardioverter-defibrillator programming. *Europace*. Sep 2010; 12(9): 1245-50. PMID 20650939
38. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med*. Nov 27 1997; 337(22): 1576-83. PMID 9411221
39. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). *Circulation*. Aug 15 2000; 102(7): 748-54. PMID 10942742
40. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation*. Mar 21 2000; 101(11): 1297-302. PMID 10725290
41. Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. *Circulation*. May 06 2003; 107(17): 2221-6. PMID 12695290
42. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. *Circulation*. Apr 15 1995; 91(8): 2195-203. PMID 7697849
43. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. *J Am Coll Cardiol*. May 07 2003; 41(9): 1573-82. PMID 12742300
44. National Institute for Health and Care Excellence (NICE). Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (Review of TA95 and TA120). 2013; <https://www.nice.org.uk/guidance/ta314/documents/arrhythmias-icds-heart-failure-cardiac-resynchronisation-fad-document2>. Accessed April 3, 2022.
45. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS

- studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J*. Dec 2000; 21(24): 2071-8. PMID 11102258
46. Betts TR, Sadarmin PP, Tomlinson DR, et al. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis. *Europace*. Jun 2013; 15(6): 813-9. PMID 23365069
 47. Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. *J Am Coll Cardiol*. May 03 2005; 45(9): 1474-81. PMID 15862422
 48. Persson R, Earley A, Garlitski AC, et al. Adverse events following implantable cardioverter defibrillator implantation: a systematic review. *J Interv Card Electrophysiol*. Aug 2014; 40(2): 191-205. PMID 24948126
 49. Ezzat VA, Lee V, Ahsan S, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation?. *Open Heart*. NA 2015; 2(1): e000198. PMID 25745566
 50. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. *Eur Heart J*. May 2014; 35(18): 1186-94. PMID 24347317
 51. van Rees JB, de Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. *J Am Coll Cardiol*. Aug 30 2011; 58(10): 995-1000. PMID 21867832
 52. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. *Heart Rhythm*. Feb 2016; 13(2): 443-54. PMID 26385533
 53. Food and Drug Administration. Premature Insulation Failure in Recalled Riata Implantable Cardioverter Defibrillator (ICD) Leads Manufactured by St. Jude Medical, Inc.: FDA Safety Communication. 2014; <https://wayback.archive-it.org/7993/20170722215745/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm314930.htm>. Accessed April 4, 2022.
 54. Hauser RG, Katsiyannis WT, Gornick CC, et al. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. *Europace*. Mar 2010; 12(3): 395-401. PMID 19946113
 55. Providencia R, Kramer DB, Pimenta D, et al. Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies. *J Am Heart Assoc*. Oct 30 2015; 4(11). PMID 26518666

56. Birnie DH, Parkash R, Exner DV, et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. *Circulation*. Mar 13 2012; 125(10): 1217-25. PMID 22311781
57. Hauser RG, Maisel WH, Friedman PA, et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management. *Circulation*. Feb 01 2011; 123(4): 358-63. PMID 21242478
58. Gould PA, Gula LJ, Champagne J, et al. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. *Heart Rhythm*. Dec 2008; 5(12): 1675-81. PMID 19084804
59. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. *Circulation*. Oct 19 2010; 122(16): 1553-61. PMID 20921437
60. Ricci RP, Pignalberi C, Magris B, et al. Can we predict and prevent adverse events related to high-voltage implantable cardioverter defibrillator lead failure?. *J Interv Card Electrophysiol*. Jan 2012; 33(1): 113-21. PMID 21882010
61. Cheng A, Wang Y, Curtis JP, et al. Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. *J Am Coll Cardiol*. Nov 09 2010; 56(20): 1651-6. PMID 21050975
62. Faulknier BA, Traub DM, Aktas MK, et al. Time-dependent risk of Fidelis lead failure. *Am J Cardiol*. Jan 01 2010; 105(1): 95-9. PMID 20102898
63. Smit J, Korup E, Schonheyder HC. Infections associated with permanent pacemakers and implanted cardioverter-defibrillator devices. A 10-year regional study in Denmark. *Scand J Infect Dis*. Sep 2010; 42(9): 658-64. PMID 20465488
64. Nery PB, Fernandes R, Nair GM, et al. Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. *J Cardiovasc Electrophysiol*. Jul 2010; 21(7): 786-90. PMID 20102431
65. Sohail MR, Hussain S, Le KY, et al. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. *J Interv Card Electrophysiol*. Aug 2011; 31(2): 171-83. PMID 21365264
66. Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. *Ann Intern Med*. Oct 17 2000; 133(8): 604-8. PMID 11033588
67. Borleffs CJ, Thijssen J, de Bie MK, et al. Recurrent implantable cardioverter-defibrillator replacement is associated with an increasing risk of pocket-related

- complications. *Pacing Clin Electrophysiol.* Aug 2010; 33(8): 1013-9. PMID 20456647
68. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. *J Am Coll Cardiol.* Apr 08 2008; 51(14): 1357-65. PMID 18387436
 69. Tan VH, Wilton SB, Kuriachan V, et al. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. *Circ Arrhythm Electrophysiol.* Feb 2014; 7(1): 164-70. PMID 24446023
 70. Sterns LD, Meine M, Kurita T, et al. Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. *Heart Rhythm.* Jul 2016; 13(7): 1489-96. PMID 26988379
 71. Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. *Heart Rhythm.* May 2015; 12(5): 926-36. PMID 25637563
 72. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. *J Am Coll Cardiol.* Feb 23 2010; 55(8): 774-82. PMID 20170816
 73. Furniss G, Shi B, Jimenez A, et al. Cardiac troponin levels following implantable cardioverter defibrillation implantation and testing. *Europace.* Feb 2015; 17(2): 262-6. PMID 25414480
 74. Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. *Circulation.* Jan 05 2021; 143(1): 7-17. PMID 33073614
 75. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. *J Am Coll Cardiol.* Apr 28 2015; 65(16): 1605-1615. PMID 25908064
 76. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. *Eur Heart J.* Jul 01 2014; 35(25): 1657-65. PMID 24670710
 77. Olde Nordkamp LR, Brouwer TF, Barr C, et al. Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. *Int J Cardiol.* Sep 15 2015; 195: 126-33. PMID 26026928
 78. Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The

- EFFORTLESS Study. *J Am Coll Cardiol*. Aug 15 2017; 70(7): 830-841. PMID 28797351
79. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. *Circulation*. Aug 27 2013; 128(9): 944-53. PMID 23979626
 80. Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. *Heart Rhythm*. Jan 2016; 13(1): 157-64. PMID 26341604
 81. Lambiase PD, Gold MR, Hood M, et al. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. *Heart Rhythm*. May 2016; 13(5): 1066-1074. PMID 26767422
 82. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med*. Jul 01 2010; 363(1): 36-44. PMID 20463331
 83. Theuns DA, Crozier IG, Barr CS, et al. Longevity of the Subcutaneous Implantable Defibrillator: Long-Term Follow-Up of the European Regulatory Trial Cohort. *Circ Arrhythm Electrophysiol*. Oct 2015; 8(5): 1159-63. PMID 26148819
 84. Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. *J Am Coll Cardiol*. Nov 06 2012; 60(19): 1933-9. PMID 23062537
 85. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. *N Engl J Med*. Aug 06 2020; 383(6): 526-536. PMID 32757521
 86. Mithani AA, Kath H, Hunter K, et al. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement. *Europace*. Feb 01 2018; 20(2): 308-314. PMID 28383717
 87. Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. *Int J Cardiol*. Feb 01 2017; 228: 280-285. PMID 27865198
 88. Kobe J, Hucklenbroich K, Geisendorfer N, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. *Clin Res Cardiol*. May 2017; 106(5): 317-321. PMID 27878381
 89. Pedersen SS, Mastenbroek MH, Carter N, et al. A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator

- System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life Substudy). *Am J Cardiol.* Aug 15 2016; 118(4): 520-6. PMID 27353211
90. Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. *J Am Coll Cardiol.* Nov 08 2016; 68(19): 2047-2055. PMID 27810043
 91. Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. *JAMA Cardiol.* Nov 01 2016; 1(8): 900-911. PMID 27603935
 92. Kobe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. *Heart Rhythm.* Jan 2013; 10(1): 29-36. PMID 23032867
 93. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* Apr 01 2022: 101161CIR0000000000001062. PMID 35363500
 94. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* Jan 22 2013; 61(3): e6-75. PMID 23265327
 95. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* Oct 02 2018; 72(14): 1677-1749. PMID 29097294
 96. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* Dec 22 2020; 142(25): e533-e557. PMID 33215938
 97. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. *J Am Coll Cardiol.* Sep 16 2014; 64(11): 1143-77. PMID 24820349
 98. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific

- statement from the American Heart Association. *Circulation*. Jan 26 2010; 121(3): 458-77. PMID 20048212
99. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*. Nov 2019; 16(11): e301-e372. PMID 31078652
100. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*. Dec 2013; 10(12): 1932-63. PMID 24011539
101. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). *Can J Cardiol*. Oct 2014; 30(10): e1-e63. PMID 25262867
102. Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of Cardiology (ACC), the American Heart Association (AHA), and the Association for European Paediatric and Congenital Cardiology (AEPC) Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). *JACC Clin Electrophysiol*. Nov 2021; 7(11): 1437-1472. PMID 34794667
103. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). 2018; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=288>. Accessed April 4, 2022.